RP103
ID: 6248ffb87aaac8765507df0f
2 Documentos
Cerrar
2 Referencias ( articles) loading Revertir Estudificar

Estudio primario

No clasificado

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Registro de estudios ClinicalTrials.gov
Año 2014
Enlaces Registro de estudios

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
The purpose of this study is to evaluate the effect of cysteamine in patients with symptomatic Huntington\'s disease by comparing two groups of patients (cysteamine vs placebo) on the results of the Unified Huntington\'s Disease Rating Scale (UHDRS, Huntington study group 1996).

Estudio primario

No clasificado

A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease.

Revista Movement disorders : official journal of the Movement Disorder Society
Año 2017
Enlaces Pubmed DOI

Este artículo está incluido en 1 Revisión sistemática Revisiones sistemáticas (1 referencia)

Cargando información sobre las referencias
<b>BACKGROUND: </b>Cysteamine has been demonstrated as potentially effective in numerous animal models of Huntington's disease.<b>METHODS: </b>Ninety-six patients with early-stage Huntington's disease were randomized to 1200 mg delayed-release cysteamine bitartrate or placebo daily for 18 months. The primary end point was the change from baseline in the UHDRS Total Motor Score. A linear mixed-effects model for repeated measures was used to assess treatment effect, expressed as the least-squares mean difference of cysteamine minus placebo, with negative values indicating less deterioration relative to placebo.<b>RESULTS: </b>At 18 months, the treatment effect was not statistically significant - least-squares mean difference, -1.5 ± 1.71 (P = 0.385) - although this did represent less mean deterioration from baseline for the treated group relative to placebo. Treatment with cysteamine was safe and well tolerated.<b>CONCLUSIONS: </b>Efficacy of cysteamine was not demonstrated in this study population of patients with Huntington's disease. Post hoc analyses indicate the need for definitive future studies. © 2017 International Parkinson and Movement Disorder Society.